Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.

Aguilar, E J; Ricciuti, B; Gainor, J F; Kehl, K L; Kravets, S; Dahlberg, S; Nishino, M; Sholl, L M; Adeni, A; Subegdjo, S; Khosrowjerdi, S; Peterson, R M; Digumarthy, S; Liu, C; Sauter, J; Rizvi, H; Arbour, K C; Carter, B W; Heymach, J V; Altan, M; Hellmann, M D; Awad, M M

Aguilar, E J; Ricciuti, B; Gainor, J F; Kehl, K L; Kravets, S; Dahlberg, S; Nishino, M; Sholl, L M; Adeni, A; Subegdjo, S; Khosrowjerdi, S; Peterson, R M; Digumarthy, S; Liu, C; Sauter, J; Rizvi, H; Arbour, K C; Carter, B W; Heymach, J V; Altan, M; Hellmann, M D; Awad, M M.

Affiliation

Aguilar EJ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.
Ricciuti B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.
Gainor JF; Department of Medicine, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, USA.
Kehl KL; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.
Kravets S; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, USA.
Dahlberg S; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, USA.
Nishino M; Departments of Radiology, Brigham and Women's Hospital, Boston, USA.
Sholl LM; Departments of Pathology, Brigham and Women's Hospital, Boston, USA.
Adeni A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.
Subegdjo S; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA.
Khosrowjerdi S; Department of Medicine, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, USA.
Peterson RM; Department of Medicine, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, USA.
Digumarthy S; Department of Medicine, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, USA.
Liu C; Departments of Radiology, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA.
Sauter J; Departments of Pathology, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA.
Rizvi H; Departments of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA.
Arbour KC; Departments of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA.
Carter BW; Departments of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Heymach JV; Departments of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Altan M; Departments of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Hellmann MD; Departments of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, USA.
Awad MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address: mark_awad@dfci.harvard.edu.

Ann Oncol ; 30(10): 1653-1659, 2019 10 01.

Article in En | MEDLINE | ID: mdl-31435660

Subject(s)

Adenocarcinoma of Lung/mortality; Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Agents, Immunological/therapeutic use; B7-H1 Antigen/metabolism; Carcinoma, Non-Small-Cell Lung/mortality; Carcinoma, Squamous Cell/mortality; Lung Neoplasms/mortality; Adenocarcinoma of Lung/drug therapy; Adenocarcinoma of Lung/immunology; Adenocarcinoma of Lung/pathology; Adult; Aged; Aged, 80 and over; B7-H1 Antigen/antagonists & inhibitors; Biomarkers, Tumor/immunology; Biomarkers, Tumor/metabolism; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/immunology; Carcinoma, Non-Small-Cell Lung/pathology; Carcinoma, Squamous Cell/drug therapy; Carcinoma, Squamous Cell/immunology; Carcinoma, Squamous Cell/pathology; Female; Follow-Up Studies; Humans; Lung Neoplasms/drug therapy; Lung Neoplasms/immunology; Lung Neoplasms/pathology; Male; Middle Aged; Patient Selection; Prognosis; Retrospective Studies; Survival Rate

Key words

NSCLC; PD-L1; pembrolizumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / B7-H1 Antigen / Antineoplastic Agents, Immunological / Adenocarcinoma of Lung / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Year: 2019 Document type: Article

Fulltext

XML

PubMed Links

Search on Google